 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH Mereo or the Company, a clinical-stage biopharmaceutical company focused on rare diseases, today provided a general business update, including a current assessment of the impact of the coronavirus disease COVID-19 pandemic on the business. The Company also announced a directorate change. The Companys foremost concerns are to respect both the health of the osteogenesis imperfecta OI and alpha-1 antitrypsin deficiency patient communities and clinical trial participants, as well as the pressures that healthcare systems are currently facing due to the COVID-19 pandemic. 